{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:31:31Z","timestamp":1777905091445,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Identification of variants of uncertain significance (VUS) presents a great challenge in oncogenetics, especially in the era of personalised cancer treatment. We present a metastatic pancreatic cancer patient, referred for predictive genetic testing for treatment with poly(ADP-ribose) polymerase (PARP) inhibitors, in whom a rare missense BRCA2:c.7892\u2009T\u2009&gt;\u2009C p.(Leu2631Pro), located in the DNA-binding domain, was identified. Extensive family history of cancers as well as data on other carriers, identified in our laboratory database of tested individuals, suggested hereditary breast and ovarian cancer (HBOC) syndrome. However, the variant could only be formally classified as a VUS at the time. In this exceptional case, an ad hoc board of experts was formed and proposed the patient be offered PARP inhibitors before time-consuming cosegregation analysis and formal reclassification of the VUS to pathogenic\/likely pathogenic (P\/LP) were completed. After a partial response to platinum-based chemotherapy, the patient consented to maintenance with olaparib and a 48-months long complete response was observed. Herein, we also present a formal reclassification of the variant BRCA2:c.7892\u2009T\u2009&gt;\u2009C from VUS to pathogenic after the completion of extensive cosegregation analysis in 71 members of a single large family originating from a specific northeastern region of Slovenia.<\/jats:p>","DOI":"10.1038\/s44276-026-00206-0","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:01:07Z","timestamp":1771246867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2:c.7892\u2009T\u2009&gt;\u2009C variant enables its reclassification from VUS to pathogenic"],"prefix":"10.1038","volume":"4","author":[{"given":"Ksenija","family":"Strojnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Blatnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Novakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Ignjatovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janja","family":"Ocvirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vida","family":"Stegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"\u0160kerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u0161per","family":"Klan\u010dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdjan","family":"Novakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vita","family":"\u0160etraj\u010di\u010d Drago\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"206_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmedgenet-2018-105872","volume":"56","author":"AB Spurdle","year":"2019","unstructured":"Spurdle AB, Greville-Heygate S, Antoniou AC, Brown M, Burke L, de la Hoya M, et al. Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. J Med Genet. 2019;56:347\u201357. https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2018-105872.","journal-title":"J Med Genet"},{"key":"206_CR2","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","volume":"26","author":"EB Eccles","year":"2015","unstructured":"Eccles EB, Mitchell G, Monteiro ANA, Schmutzler R, Couch FJ, Spurdle AB, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015;26:2057\u201365.","journal-title":"Ann Oncol"},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC, Brown K, et al. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA. 2018;320:1266\u201374. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30264118.","journal-title":"JAMA"},{"key":"206_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41431-023-01380-2","volume":"31","author":"J Henkel","year":"2023","unstructured":"Henkel J, Laner A, Locher M, Wohlfrom T, Neitzel B, Becker K, et al. Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients. Eur J Hum Genet. 2023;31:925\u201330.","journal-title":"Eur J Hum Genet"},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/jmg-2023-109694","volume":"61","author":"G Innella","year":"2024","unstructured":"Innella G, Ferrari S, Miccoli S, Luppi E, Fortuno C, Parsons MT, et al. Clinical implications of VUS reclassification in a single-centre series from application of ACMG\/AMP classification rules specified for BRCA1\/2. J Med Genet. 2024;61:483\u20139.","journal-title":"J Med Genet"},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bi\u00e8che I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35:588\u2013606.","journal-title":"Ann Oncol"},{"key":"206_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3390\/cancers14061434","volume":"14","author":"Stegel","year":"2022","unstructured":"Stegel, Blatnik V, \u0160kof A, Drago\u0161 V\u0160 E, Krajc M, Gregori\u010d B, et al. Real-world data on detection of germline and somatic pathogenic\/likely pathogenic variants in BRCA1\/2 and other susceptibility genes in ovarian cancer patients using next generation sequencing. Cancers. 2022;14:1434. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35326583.","journal-title":"Cancers"},{"key":"206_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/genes11030325","volume":"11","author":"G Klan\u010dar","year":"2020","unstructured":"Klan\u010dar G, Blatnik A, \u0160etraj\u010di\u010d Drago\u0161 V, Vogri\u010d V, Stegel V, Blatnik O, et al. A novel germline MLH1 in-frame deletion in a slovenian lynch syndrome family associated with uncommon isolated PMS2 loss in tumor tissue. Genes. 2020;11:325. https:\/\/www.mdpi.com\/2073-4425\/11\/3\/325.","journal-title":"Genes"},{"key":"206_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5535-2","volume":"19","author":"A Gornjec","year":"2019","unstructured":"Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, et al. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1\/2 genes in patients with tubo-ovarian high grade serous carcinoma. BMC Cancer. 2019;19:296. https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5535-2.","journal-title":"BMC Cancer"},{"key":"206_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201323. https:\/\/www.nature.com\/doifinder\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"206_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ajhg.2016.04.003","volume":"98","author":"GP Jarvik","year":"2016","unstructured":"Jarvik GP, Browning BL. Consideration of cosegregation in the pathogenicity classification of genomic variants. Am J Hum Genet. 2016;98:1077\u201381.","journal-title":"Am J Hum Genet"},{"key":"206_CR12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41436-020-0920-4","volume":"22","author":"S Belman","year":"2020","unstructured":"Belman S, Parsons MT, Spurdle AB, Goldgar DE, Feng BJ. Considerations in assessing germline variant pathogenicity using cosegregation analysis. Genet Med. 2020;22:2052\u20139.","journal-title":"Genet Med"},{"key":"206_CR13","doi-asserted-by":"crossref","unstructured":"Mohammadi L, Vreeswijk MP, Oldenburg R, van den Ouweland A, Oosterwijk JC, van der Hout AH, et al. A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer. 2009;9:211.","DOI":"10.1186\/1471-2407-9-211"},{"key":"206_CR14","doi-asserted-by":"crossref","unstructured":"Parsons MT, de la Hoya M, Richardson ME, Tudini E, Anderson M, Berkofsky-Fessler W, et al. Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel. Am J Hum Genet. 2024;111:2044\u201358.","DOI":"10.1016\/j.ajhg.2024.07.013"},{"key":"206_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13053-025-00309-8","volume":"23","author":"T Ker\u0161evan","year":"2025","unstructured":"Ker\u0161evan T, Kogov\u0161ek T, Blatnik A, Krajc M. Analysis of informed consent forms of patients undergoing cancer genetic testing in the era of next-generation sequencing. Hered Cancer Clin Pract. 2025;23:1\u20139.","journal-title":"Hered Cancer Clin Pract"},{"key":"206_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-24991-9","volume":"15","author":"A Maver","year":"2025","unstructured":"Maver A, Juvan P, Kotnik U, Lovrecic L, Bergant G, Peterlin B. Creating the Slovenian genome database and browser as a source of comprehensive variation of the Slovenian population. Sci Rep. 2025;15:41118. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/41266748.","journal-title":"Sci Rep"},{"key":"206_CR17","doi-asserted-by":"crossref","unstructured":"Huang H, Hu C, Na J, Hart SN, Gnanaolivu RD, Abozaid M, et al. Functional evaluation and clinical classification of BRCA2 variants. Nature. 2025;111:584\u201393.","DOI":"10.1038\/s41586-024-08388-8"},{"key":"206_CR18","doi-asserted-by":"crossref","unstructured":"Sahu S, Galloux M, Southon E, Caylor D, Sullivan T, Arnaudi M, et al. Saturation genome editing-based clinical classification of BRCA2 variants. Nature. 2025;638:538\u201345.","DOI":"10.1038\/s41586-024-08349-1"},{"key":"206_CR19","doi-asserted-by":"crossref","unstructured":"Zuntini R, Ferrari S, Bonora E, Buscherini F, Bertonazzi B, Grippa M, et al. Dealing With BRCA1\/2 unclassified variants in a cancer genetics clinic: does cosegregation analysis help? Front Genet. 2018;9:378.","DOI":"10.3389\/fgene.2018.00378"},{"key":"206_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:1\u201310.","journal-title":"PLoS Med"},{"key":"206_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14235953","volume":"14","author":"KH Buckley","year":"2022","unstructured":"Buckley KH, Niccum BA, Maxwell KN, Katona BW. Gastric cancer risk and pathogenesis in BRCA1 and BRCA2 carriers. Cancers. 2022;14:1\u201315.","journal-title":"Cancers"},{"key":"206_CR22","doi-asserted-by":"publisher","first-page":"115051","DOI":"10.1016\/j.ejca.2024.115051","volume":"212","author":"J M\u2019Baloula","year":"2024","unstructured":"M\u2019Baloula J, Tougeron D, Boil\u00e8ve A, Jeanbert E, Guimbaud R, Ben Abdelghani M, et al. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: a French retrospective multicentric AGEO real-world study. Eur J Cancer. 2024;212:115051. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39366210.","journal-title":"Eur J Cancer"},{"key":"206_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-007-9729-y","volume":"110","author":"T Anagnostopoulos","year":"2008","unstructured":"Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, et al. G1738R is a BRCA1 founder mutation in Greek breast\/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat. 2008;110:377\u201385.","journal-title":"Breast Cancer Res Treat"},{"key":"206_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423008244.","journal-title":"Ann Oncol"},{"key":"206_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00280-023-04585-w","volume":"92","author":"AM Militello","year":"2023","unstructured":"Militello AM, Orsi G, Cavaliere A, Niger M, Avallone A, Salvatore L, et al. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes. Cancer Chemother Pharmacol. 2023;92:501\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"key":"206_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41436-019-0740-6","volume":"22","author":"JN Dines","year":"2020","unstructured":"Dines JN, Shirts BH, Slavin TP, Walsh T, King MC, Fowler DM, et al. Systematic misclassification of missense variants in BRCA1 and BRCA2 \u201ccoldspots. Genet Med. 2020;22:825\u201330.","journal-title":"Genet Med"},{"key":"206_CR27","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.gim.202","volume":"24","author":"H Li","year":"2022","unstructured":"Li H, Engel C, Hoya M, Peterlongo P, Yannoukakos D, Livraghi L, et al. Erratum: Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants (Genetics in Medicine. Genet Med. 2022;24:2208. https:\/\/doi.org\/10.1016\/j.gim.202.","journal-title":"Genet Med"},{"key":"206_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ajhg.2021.02.005","volume":"108","author":"ME Richardson","year":"2021","unstructured":"Richardson ME, Hu C, Lee KY, LaDuca H, Fulk K, Durda KM, et al. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. Am J Hum Genet. 2021;108:458\u201368.","journal-title":"Am J Hum Genet"}],"updated-by":[{"DOI":"10.1038\/s44276-026-00217-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000}}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00206-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00206-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00206-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:45:14Z","timestamp":1775195114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00206-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1038\/s44276-026-00206-0","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: During the correction process table 1 has been omitted.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s44276-026-00217-x","URL":"https:\/\/doi.org\/10.1038\/s44276-026-00217-x","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Participants have signed the informed consent for genetic testing and have given permission for their pseudonymised data to be used for research purposes and publishing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"5"}}